Skip to main content
Erschienen in: Pediatric Cardiology 4/2021

08.03.2021 | Original Article

Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease

verfasst von: Hiroya Masuda, Ryusuke Ae, Taka-aki Koshimizu, Masami Matsumura, Koki Kosami, Kanako Hayashida, Nobuko Makino, Yuri Matsubara, Teppei Sasahara, Yosikazu Nakamura

Erschienen in: Pediatric Cardiology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

A giant coronary artery (CA) aneurysm is a potentially fatal cardiac complication resulting from Kawasaki disease (KD). We aimed to identify epidemiologic characteristics and potential risk factors associated with giant CA aneurysms identified after acute KD. We analyzed 90,252 patients diagnosed with KD from 2011 to 2018, using data obtained in nationwide KD surveys conducted in Japan. Multivariable logistic regression analyses were performed to evaluate potential risk factors associated with subsequent giant CA aneurysm complications (defined as lumen size ≥ 8 mm), adjusting for all potential factors. Giant CA aneurysms were identified in 144 patients (0.16%) after acute KD. The annual prevalence ranged from 0.07 to 0.20% during the study period. In the multivariate analyses, male sex (adjusted odds ratio 2.09 [95% confidence interval 1.41–3.11], recurrent KD (1.90 [1.09–3.33]), IVIG administration at 1–4 days of illness (1.49 [1.04–2.15]) and ≥ 8 days after KD onset (2.52 [1.38–4.60]; reference, 5–7 days), detection of CA dilatations and aneurysms at initial echocardiography (4.17 [1.85–5.41] and 46.5 [28.8–74.8], respectively), and resistance to IVIG treatment (6.09 [4.23–8.75]) were significantly associated with giant CA aneurysm complications identified after acute KD. The annual prevalence of giant CA aneurysms identified after acute KD did not increase during the study period. Patients with larger CA abnormalities detected at initial echocardiography were independently associated with progression to giant CA aneurysm complications after acute KD regardless of the number of days from onset at treatment initiation.
Literatur
3.
Zurück zum Zitat McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135(17):e927–e999. https://doi.org/10.1161/cir.0000000000000484CrossRefPubMed McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135(17):e927–e999. https://​doi.​org/​10.​1161/​cir.​0000000000000484​CrossRefPubMed
7.
15.
Zurück zum Zitat Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, Tsuda E, Nakajima H, Matsuura H, Ikeda K, Nishigaki K, Suzuki H, Takahashi K, Suda K, Kamiyama H, Onouchi Y, Kobayashi T, Yokoi H, Sakamoto K, Ochi M, Kitamura S, Hamaoka K, Senzaki H, Kimura T (2020) JCS/JSCS 2020 Guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J 84(8):1348–1407. https://doi.org/10.1253/circj.CJ-19-1094CrossRefPubMed Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, Tsuda E, Nakajima H, Matsuura H, Ikeda K, Nishigaki K, Suzuki H, Takahashi K, Suda K, Kamiyama H, Onouchi Y, Kobayashi T, Yokoi H, Sakamoto K, Ochi M, Kitamura S, Hamaoka K, Senzaki H, Kimura T (2020) JCS/JSCS 2020 Guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J 84(8):1348–1407. https://​doi.​org/​10.​1253/​circj.​CJ-19-1094CrossRefPubMed
16.
Zurück zum Zitat Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version) (2014). Pediatr Int 56(2):135–158. doi:https://doi.org/10.1111/ped.12317 Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version) (2014). Pediatr Int 56(2):135–158. doi:https://​doi.​org/​10.​1111/​ped.​12317
18.
Zurück zum Zitat Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, Kamada M, Shiono J, Suda K, Tsuchiya K, Nakamura T, Nakamura Y, Nomura Y, Hamada H, Fukazawa R, Furuno K, Matsuura H, Matsubara T, Miura M, Takahashi K (2020) Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). PediatrInt 62(10):1135–1138. https://doi.org/10.1111/ped.14326CrossRef Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, Kamada M, Shiono J, Suda K, Tsuchiya K, Nakamura T, Nakamura Y, Nomura Y, Hamada H, Fukazawa R, Furuno K, Matsuura H, Matsubara T, Miura M, Takahashi K (2020) Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). PediatrInt 62(10):1135–1138. https://​doi.​org/​10.​1111/​ped.​14326CrossRef
22.
Zurück zum Zitat Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H (1995) Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 95(4):475–479PubMed Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H (1995) Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 95(4):475–479PubMed
27.
Zurück zum Zitat Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T (2018) Infliximab for the treatment of refractory Kawasaki disease: a Nationwide Survey in Japan. J Pediatr 195:115-120.e113. https://doi.org/10.1016/j.jpeds.2017.10.013CrossRefPubMed Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T (2018) Infliximab for the treatment of refractory Kawasaki disease: a Nationwide Survey in Japan. J Pediatr 195:115-120.e113. https://​doi.​org/​10.​1016/​j.​jpeds.​2017.​10.​013CrossRefPubMed
29.
Zurück zum Zitat Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A (2011) Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 30(10):871–876. https://doi.org/10.1097/INF.0b013e318220c3cfCrossRefPubMed Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A (2011) Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 30(10):871–876. https://​doi.​org/​10.​1097/​INF.​0b013e318220c3cf​CrossRefPubMed
33.
Zurück zum Zitat Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379(9826):1613–1620. https://doi.org/10.1016/s0140-6736(11)61930-2CrossRefPubMed Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379(9826):1613–1620. https://​doi.​org/​10.​1016/​s0140-6736(11)61930-2CrossRefPubMed
Metadaten
Titel
Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease
verfasst von
Hiroya Masuda
Ryusuke Ae
Taka-aki Koshimizu
Masami Matsumura
Koki Kosami
Kanako Hayashida
Nobuko Makino
Yuri Matsubara
Teppei Sasahara
Yosikazu Nakamura
Publikationsdatum
08.03.2021
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 4/2021
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-021-02571-8

Weitere Artikel der Ausgabe 4/2021

Pediatric Cardiology 4/2021 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.